Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Valent

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
A multilocus technique for risk evaluation of patients with neuroblastomaInge M Ambros, Bettina Brunner, Gerhard Aigner, et al.
Annales De Pathologie|July 2, 2019
[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting]Aurélie Maran-Gonzalez, Camille Franchet, Raphaëlle Duprez-Paumier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Prognostic impact of gene expression-based classification for neuroblastomaAndré Oberthuer, Barbara Hero, Frank Berthold, et al.
Cancer Communications (London, England)|November 28, 2025
Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristicsCarine Ngo, Léo Colmet-Daage, Julien Vibert, et al.
BMC Cancer|July 24, 2013
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 casesJocelyne Jacquemier, Frédérique Spyratos, Benjamin Esterni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markersAndré Oberthuer, Dilafruz Juraeva, Barbara Hero, et al.
Annales De Pathologie|August 16, 2021
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]Camille Franchet, Lounes Djerroudi, Aurélie Maran-Gonzalez, et al.
Annales De Pathologie|December 3, 2014
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]Frédérique Penault-Llorca, Anne Vincent-Salomon, Gaëtan MacGrogan, et al.
Annales De Pathologie|December 3, 2014
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]Gaëtan MacGrogan, Marie-Christine Mathieu, Bruno Poulet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2020
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation GroupInge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
A multilocus technique for risk evaluation of patients with neuroblastomaInge M Ambros, Bettina Brunner, Gerhard Aigner, et al.
Annales De Pathologie|July 2, 2019
[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting]Aurélie Maran-Gonzalez, Camille Franchet, Raphaëlle Duprez-Paumier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2010
Prognostic impact of gene expression-based classification for neuroblastomaAndré Oberthuer, Barbara Hero, Frank Berthold, et al.
Cancer Communications (London, England)|November 28, 2025
Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristicsCarine Ngo, Léo Colmet-Daage, Julien Vibert, et al.
BMC Cancer|July 24, 2013
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 casesJocelyne Jacquemier, Frédérique Spyratos, Benjamin Esterni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markersAndré Oberthuer, Dilafruz Juraeva, Barbara Hero, et al.
Annales De Pathologie|August 16, 2021
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]Camille Franchet, Lounes Djerroudi, Aurélie Maran-Gonzalez, et al.
Annales De Pathologie|December 3, 2014
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]Frédérique Penault-Llorca, Anne Vincent-Salomon, Gaëtan MacGrogan, et al.
Annales De Pathologie|December 3, 2014
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]Gaëtan MacGrogan, Marie-Christine Mathieu, Bruno Poulet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2020
Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable <i>MYCN</i>-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation GroupInge M Ambros, Gian-Paolo Tonini, Ulrike Pötschger, et al.
Pageof 6